Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/226484
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

AuthorsWeisel, Katja C.; Spencer, Andrew; Lentzsch, Suzanne; Avet-Loiseau, Hervé; Mark, Tomer M.; Špička, Ivan; Masszi, Tamas; Lauri, Birgitta; Levin, Mark-David; Bosi, Alberto; Hungria, Vania; Cavo, Michele; Lee, Je-Jung; Nooka, Ajay; Quach, Hang; Munder, Markus; Lee, Cindy; Barreto, Wolney; Corradini, Paolo; Min, Chang-Ki; Chanan-Khan, Asher A.; Horvath, Noemi; Capra, Marcelo; Beksac, Meral; Ovilla, Roberto; Jo, Jae-Cheol; Shin, Ho-Jin; Sonneveld, Pieter; Casneuf, Tineke; DeAngelis, Nikki; Amin, Himal; Ukropec, Jon; Kobos, Rachel; Mateos, Maria Victoria
KeywordsClinical trials
Multiple myeloma
Myeloma therapy
Issue Date2020
PublisherBioMed Central
CitationJournal of Hematology & Oncology 13: 115 (2020)
AbstractBackground: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). [Methods]: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10-5 sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk. [Results]: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR. [Conclusion]: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status. Trial registration: ClinicalTrials.gov, NCT02136134. Registered 12 May 2014
Description© The Author(s).
Publisher version (URL)http://dx.doi.org/10.1186/s13045-020-00948-5
URIhttp://hdl.handle.net/10261/226484
DOI10.1186/s13045-020-00948-5
E-ISSN1756-8722
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
Daratumumab_Weisel_Art2020.pdf883,3 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

10
checked on May 8, 2022

SCOPUSTM   
Citations

12
checked on May 10, 2022

WEB OF SCIENCETM
Citations

14
checked on May 13, 2022

Page view(s)

85
checked on May 16, 2022

Download(s)

57
checked on May 16, 2022

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.